Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan

Terran obtains exclusive global development and commercialization rights for idazoxan, a late-stage clinical therapeutic for schizophrenia

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Terran Biosciences, Inc., a CNS-focused biotech platform company, has entered into an agreement with French pharmaceutical company Pierre Fabre Médicament S.A.S for worldwide exclusive rights to develop and commercialize a pipeline of Pierre Fabre’s assets to treat neuropsychiatric illnesses.   The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action. Idazoxan has been tested ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters